The global Peptide Drug Conjugates market is anticipated to hold a market value of USD 861.12 Million in 2023 and USD 5,331.83 Million by 2033. The projected growth rate is nearly 20% during the forecast period from 2023 to 2033.
The robust clinical trial pipeline with peptide drug conjugates (PDCs) coupled with an increase in Research and Development investments for developing PDCs and the rising disease burden across the globe are the factors expected to contribute to the market growth. For instance, in July 2021, Takeda Pharmaceutical Company Limited in collaboration with Peptide Dream announced investing USD 3.5 billion to develop peptide drugs for neuromuscular disease.
| Report Attributes | Details |
|---|---|
| Estimated Market Value in 2023 | USD 861.12 Million |
| Estimated Market Value in 2033 | USD 5,331.83 Million |
| Projected CAGR from 2023 to 2033 | 20% |
The global peptide drug conjugates market garnered USD 717.6 Million in 2022, expanding at a historical CAGR of 16%. Pharmaceutical companies are developing PDCs for metabolic diseases and coronavirus diseases and cancer among others.
Currently, the market has two FDA-approved drugs Pepaxto (Melflufen) and Lutathera (Lu 177 dotatate) for cancer treatment. Therefore, the rising prevalence of such diseases is driving the peptide drug conjugates market. According to the National Cancer Institute, in 2020, more than 1.8 million new cancer cases and more than 600,000 deaths occurred in the USA due to cancer.
Due to the increased number of cancer cases, the pharmaceutical industry has been pushed to investigate additional drug conjugates, resulting in the development and popularity of PDCs. The estimation reveals that the PDCs market is projected to secure a market value of USD 5,331.83 Million by 2033.
Growing Technological Advancements and Financial Investments to Aid Market Growth
The strong product pipeline and increasing financial investments in research and development are offering lucrative opportunities for the peptide drug conjugates market growth. For instance, AngioChem, Inc.’s product candidate- ANG1005 indicated for brain tumors is undergoing phase 3 clinical studies, and Bicycle Therapeutics pipeline products- BT5528&BT1718 indicated for non-small cell carcinoma, are under phase 2 clinical trials. Hence, the expected new PDC approval for the treatment of multiple types of cancer will boost the market growth in the near future.
According to the national cancer institute, there are more than 250 FDA-approved chemotherapeutic drugs used in the treatment of malignant tumors. However, the major drawback associated with such small molecules is uncontrolled toxicity resulting in severe side effects. Moreover, increasing drug resistance of tumor cells to such agents has led to demand for a better treatment approach like targeted PDCs and thereby, driving the peptide drug conjugates space.
Increasing Costs to Hinder Market Growth
Low bioactivity, poor stability, long research and development time, and slow clinical development process as therapeutic agents of PDC are expected to restrain the segment, leading to an increase in overall time and cost incurred for the development.
Presence of Key Players in the Region to Increase Consumer Demand
North America dominated the overall peptide drug conjugates (PDCs) market in terms of the revenue share of 45.6% in 2022, owing to the launch of Melflufen and the rapid uptake of PDC drugs in cancer therapy.
Increasing awareness about current treatment options, favorable reimbursement policies, and improved patient affordability are the factors expected to drive market growth. Furthermore, rising cases of cancer and related mortality are fueling the market growth in the region. For instance, NCI reported approximately 1,806,590 new cancer cases and 606,520 disease-related deaths in 2020.
Increasing Investments to Develop PDCs to Boost Regional Market
Asia Pacific is expected to witness a growth rate of 27.4% during the forecast period. The growth of the region is attributed to the upsurge in the number of cancer cases and strategic initiatives undertaken by the market players for regional expansion in such regions. Furthermore, rising research and development along with increasing investments to develop and commercialize such novel delivery systems is anticipated to boost the market growth in the region.
Lutathera Product Segment to Dominate the Category
The Lutathera product segment dominated the peptide drug conjugates market with a revenue share of 80.5% in 2022. The first FDA-approved PDC is Novartis’s Lutathera (lutetium Lu 177), a radiolabeled somatostatin analog which is an advanced accelerator injection. The expected patent expiry date is 25th July 2038. It is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors including foregut, midgut, and hindgut neuroendocrine tumors in adults. Lutathera consists of an amide linkage between homing peptide somatostatin and cytotoxic radiotherapeutic agent 177Lu.
Oncopeptides AB received FDA approval for its first-in-class peptide-conjugated alkylator, Pepaxto (melflufen), in February 2021. The combination of Pepaxto (Melphalan flufenamide) with dexamethasone is indicated for multiple myeloma in adult patients. The drug has demonstrated anti-myeloma activity in myeloma tumor cells resistant to bortezomib and the alkylator melphalan. Melflufen patents cover major markets in the USA, Japan, Canada, and Europe. However, the drug has been withdrawn from the USA market in October 2021, based on overall survival data from its phase 3 study.
Therapeutic Segment Leads the Type Segment and is Projected to Dominate the Market
Therapeutic agents of PDC dominated the peptide drug conjugates market with a revenue share of 82.3% in 2022 and are anticipated to witness the fastest growth. The factors attributing to dominance is the presence of both approved PDCs, Lutathera and Pepaxtoas therapeutic agents targeting tumor cells. Moreover, the presence of targeting therapeutic drugs such as ANG1005,
BT5528 and BT1718 under clinical trials are expected to boost the market during the forecast period. Along with cancer, pharmaceutical companies are developing targeting therapeutic PDCs for metabolic diseases and coronavirus diseases due to the significant benefits of PDCs in the therapeutic segment.
PDCs coupled with radionuclides can also act as diagnostic agents. For example, Mallinckrodt Pharmaceuticals’ In-DTPA-octreotide (octreoscan) which contains radioactive nucleotides, is primarily used in the localization of neuroendocrine tumors. Furthermore, the development and applications of PDCs in diagnosis are anticipated to offer remunerative opportunities for segment growth.
The players in the market are focusing to increase their global influence and adopt strategies such as; acquisition, collaboration, and partnerships. Key players in the market include Novartis AG; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Oncopeptides AB; Angiochem Inc.; Innovasium Soricimed Biopharma; and Theratechnologies. Some of the recent key developments among key players are:
| Report Attributes | Details |
|---|---|
| Market Value in 2023 | USD 861.12 Million |
| Market Value in 2033 | USD 5,331.83 Million |
| Forecast Period | 2023 to 2033 |
| Historical Data | 2018 to 2022 |
| Quantitative Units | USD Million for Value and CAGR from 2023 to 2033 |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Segments Covered | Type, Product, Region |
| Key Companies Profiled | Novartis AG; Oncopeptides AB; Bicycle Therapeutics; AstraZeneca; Cybrexa Therapeutics; Angiochem Inc.; Innovasium Soricimed Biopharma; Theratechnologies; Coherent Biopharma; WuXI STA |
| Pricing | Available upon Request |
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Europe Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 12: Europe Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Asia Pacific Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 15: Asia Pacific Market Value (US$ Million) Forecast by Type, 2018 to 2033
Table 16: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: MEA Market Value (US$ Million) Forecast by Product, 2018 to 2033
Table 18: MEA Market Value (US$ Million) Forecast by Type, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Product, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Type, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 13: Global Market Attractiveness by Product, 2023 to 2033
Figure 14: Global Market Attractiveness by Type, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Product, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Type, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 28: North America Market Attractiveness by Product, 2023 to 2033
Figure 29: North America Market Attractiveness by Type, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Product, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Type, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Product, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Type, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Europe Market Value (US$ Million) by Product, 2023 to 2033
Figure 47: Europe Market Value (US$ Million) by Type, 2023 to 2033
Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Europe Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 55: Europe Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 58: Europe Market Attractiveness by Product, 2023 to 2033
Figure 59: Europe Market Attractiveness by Type, 2023 to 2033
Figure 60: Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Asia Pacific Market Value (US$ Million) by Product, 2023 to 2033
Figure 62: Asia Pacific Market Value (US$ Million) by Type, 2023 to 2033
Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 70: Asia Pacific Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 73: Asia Pacific Market Attractiveness by Product, 2023 to 2033
Figure 74: Asia Pacific Market Attractiveness by Type, 2023 to 2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033
Figure 76: MEA Market Value (US$ Million) by Product, 2023 to 2033
Figure 77: MEA Market Value (US$ Million) by Type, 2023 to 2033
Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: MEA Market Value (US$ Million) Analysis by Product, 2018 to 2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Product, 2023 to 2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Product, 2023 to 2033
Figure 85: MEA Market Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 88: MEA Market Attractiveness by Product, 2023 to 2033
Figure 89: MEA Market Attractiveness by Type, 2023 to 2033
Figure 90: MEA Market Attractiveness by Country, 2023 to 2033
North America will account for a major share of global Peptide Drug Conjugates demand.
From 2023 to 2033, the market is projected to expand at a 20% value CAGR, as per FMI.
By 2033, Peptide Drug Conjugates market demand is expected to reach USD 5,331.83 Million.
By 2023, demand for Peptide Drug Conjugates is forecast to be valued at USD 861.12 Million
As of 2022, the market for Peptide Drug Conjugates was valued at USD 717.6 Million
Explore Similar Insights
Peptide Drug Conjugates Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
